Medical Device News Magazine

RAIsonance, Inc. Announces BARDA Contract to Continue Development of the AudibleHealth Dx Diagnostic SaMD for COVID-19 and Influenza Through AI-Powered Cough Analysis

RAIsonance’s Forced Cough Vocalization (FCV) Signature Analysis Technology is Designed to Diagnose Respiratory Illnesses Via a Cloud-Based Diagnostic Platform and a Mobile App User Interface

About Medical Device News Magazine

About Medical Device News Magazine. We are a digital publication founded in 2008 located in the United States.

Advertise with Medical Device News Magazine! Join Our #1 Family of Advertisers!

We pride ourselves on being the best-kept secret when it comes to distributing your news! Our unique digital approach enables us to circulate your...
RAIsonance, Inc., the leader in artificial intelligence-powered analysis of FCV, announced today it has been awarded a contract from the Biomedical Advanced Research and Development Authority (BARDA), a component of the Administration for Strategic Preparedness and Response (ASPR), within the U.S. Department of Health and Human Services (HHS), a U.S. government agency.
The contract consists of just over $749,000 allocated to the continued development of RAIsonance’s AudibleHealth Dx Software as a Medical Device (SaMD). The device is designed to analyze a user’s Forced Cough Vocalization (FCV) in the diagnosis of illness, with the current focus on both COVID-19 and Influenza. The cloud-based artificial intelligence processing platform uses a mobile app interface for cough collection and is designed to deliver test results in about 2 minutes within the app. The primary objectives of the contract are to complete the execution of the clinical validation studies for COVID-19 and Influenza and to complete a de novo submission to the U.S. Food and Drug Administration before the end of 2023.

Kitty Kolding, Co-Founder and CEO at RAIsonance

“We are elated to have BARDA’s support. Their strategic guidance and extensive expertise will speed our efforts to deliver the best possible diagnostic SaMD to market and help ensure that we fulfill our mission to meaningfully impact global health with such an innovative diagnostic solution.”

RAIsonance’s SaMD is designed to use only software to diagnose disease, without any wet or biological samples of any kind. The non-invasive test requires just 10 intentional coughs, submitted via a uniquely devised mobile application. Tests can be delivered on-demand electronically, are independent of supply chains, and are not limited by shelf-life expiration. The SaMD is scalable – able to process 20,000 tests per second – an ideal solution for large organizations, colleges and universities, and government agencies.
This award is one component of BARDA’s rapidly expanding DRIVe Medical countermeasures portfolio; visit to learn more.
“This project has been supported in whole or in part with federal funds from the Department of Health and Human Services; Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority (BARDA), under contract number 75A50123C00015.”
Medical Device News Magazine
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Other News

Ultrahuman Announces its App Store ‘PowerPlugs’ with the World’s First AFib Detection Technology on a Smart Ring

Recognizing each individual’s health journey is unique, PowerPlugs enable people to choose and focus on the aspects of their health that matter most. It’s designed for highly personalized health insights, ensuring that every individual can personalize their health tracking to their unique needs and goals.

VisionAir Solutions Celebrates Milestone and New Collaboration

This achievement marks VisionAir Solutions commitment to bringing technological innovation to pulmonary medicine. Since its acquisition by Theken Companies last year, VAS has over doubled its growth and continues to demonstrate industry adoption and the advantages of personalized healthcare.

ArisGlobal Reports | Newest Version of LifeSphere® Regulatory Platform Launches

Ann-Marie Orange, CIO & Global Head of R&D shares, “With more than 35 years of experience in life sciences technology, ArisGlobal is the only technology company offering strong Safety, Regulatory, and Quality Management solutions powered with next-generation cognitive computing, delivering unmatched interoperability across the R&D IT ecosystem. Over the last 18 months ArisGlobal has made significant investment in the strategic acquisitions of Amplexor Life Sciences and SPORIFY, along with technology R&D – and we’re not stopping.”